ASSEMBLY BIOSCIENCES, INC. cotiza a 22.77 USD y tiene una capitalización bursátil de $464M. En los últimos 12 meses ha facturado $75M con un margen de flujo de caja libre del -56.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250,…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.20 | $-0.54 | $2.48 | $-0.72 |
| Estimado | $-0.67 | $-0.64 | $-0.85 | $-0.65 |
| Sorpresa | +70.1% | +15.6% | +391.8% | -10.8% |
| Métrica | ASMB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -16.8% | -38.6% | +21.9% |
| Net Margin | -8.5% | -33.6% | +25.1% |
| FCF Margin | -56.9% | -13.9% | -43.1% |
| ROE | -3.0% | -40.4% | +37.4% |
| ROA | -2.4% | -32.0% | +29.6% |
| Current Ratio | 5.22 | 2.84 | +2.38 |
| Debt / Equity | — | 0.28 | — |